Remogliflozin Etabonate, a Selective Inhibitor of the Sodium-Glucose Transporter 2, Improves Serum Glucose Profiles in Type 1 Diabetes

OBJECTIVE: Remogliflozin etabonate (RE), an inhibitor of the sodium-glucose transporter 2, improves glucose profiles in type 2 diabetes. This study assessed safety, tolerability, pharmacokinetics, and pharmacodynamics of RE in subjects with type 1 diabetes. RESEARCH DESIGN AND METHODS: Ten subjects...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Mudaliar, Sunder, Armstrong, Debra A., Mavian, Annie A., O’Connor-Semmes, Robin, Mydlow, Patricia K., Ye, June, Hussey, Elizabeth K., Nunez, Derek J., Henry, Robert R., Dobbins, Robert L.
Formato: Artigo
Idioma:Inglês
Publicado em: American Diabetes Association 2012
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3476920/
https://ncbi.nlm.nih.gov/pubmed/23011728
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/dc12-0508
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados